QNTM Quantum BioPharma Corp: Enterprise Value to EBITDA Ratio
The linear price action on the chart helps assess the growth trajectory of Quantum BioPharma Ltd (QNTM), which utilizes AI to develop treatments for inflammation and neuronal degeneration. The current EV/EBITDA ratio stands at 0.00. Efficiency is declining due to the fragmentation of small assets and the absence of a primary profit generator. Meanwhile, Quantum BioPharma Ltd (QNTM) operates as a research hub, outsourcing synthesis and testing to third-party contractors.
Comprehensive metric breakdowns and analytics for quantumbiopharma.com (QNTM)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Quantum BioPharma Ltd|QNTM - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Quantum BioPharma|QNTM - Company Total Indebtedness|Debt to Book Value Quantum BioPharma Corp|QNTM - Company Long-Term Debts|Company Short-Term Debts Quantum BioPharma|Quick Liquidity quantumbiopharma.com
- financial results and valuation multiples details:
QNTM - Company Profit|Future Profit Quantum BioPharma Ltd|QNTM - Market Price to Net Income Ratio|Projected Price to Earnings Quantum BioPharma Ltd|QNTM - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Quantum BioPharma Corp|QNTM - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Quantum BioPharma|QNTM - Earnings per share for the trailing year|Quarterly EPS earnings growth quantumbiopharma.com|QNTM - Earnings per share growth in current year|Earnings growth forecast for next year Quantum BioPharma Ltd
Basic company analysis:Quantum BioPharma Limited (QNTM)
Minimum sales volumes and a lack of pricing power at Quantum BioPharma Ltd (QNTM) render operating profit extremely volatile. This ratio correlates the total enterprise value, including debt, with its ability to generate pre-tax cash flow, allowing for a real-time assessment of capitalization scale via the company's current EV/EBITDA value and determining the extent of asset overvaluation during the restructuring period.
Competitors of Quantum BioPharma Ltd
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ANI Pharmaceuticals, Inc. ANIP|Enterprise Value to EBITDA Multiple MannKind Corp|AMPH: Enterprise Value to EBITDA Ratio|PCRX - EV/EBITDA Multiple|SPRY: EV/EBITDA Multiple|theravance.com (TBPH) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aquestive Therapeutics, Inc.|Enterprise Value to Operating Income Before Depreciation SCPH (scPharma)|Enterprise Value to EBITDA Ratio TECX (Tectonic Therapeutic, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio TNXP|China SXT Pharmaceuticals, Inc. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Eupraxia Pharmaceuticals, Inc. EPRX|BHST - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Invizyne Technologies (EXOZ) - Enterprise Value to EBITDA Ratio|ORMP (oramed.com) - Enterprise Value to EBITDA Ratio|Entera Bio - Business Value to Operating Income Before Depreciation|HYFT (MindWalk Holdings) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ABVC|EV/EBITDA Multiple CPIX|Total Company Value to Operating Income Before Depreciation Ratio FibroGen Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Telomir Pharma TELO|Rani Therapeutics Holdings (RANI) - Company Value to EBITDA|SNYR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio RLYB|LEXX: EV/EBITDA Multiple|Pulmatrix Inc - Business Value to Operating Income Before Depreciation|PTHL (Pheton Holdings Limited) - EV/EBITDA Multiple|EV/EBITDA Multiple Aptorum|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lyra Therapeutics, Inc. (LYRA)|IBO (impactbiomedinc.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TNF Pharmaceuticals, Inc. TNFA|YCBD - Enterprise Value to EBITDA Ratio|PainReform Limited - EV/EBITDA Multiple|CYTO - EV/EBITDA Multiple|LIPO (Lipella Pharmaceuticals) - Enterprise Value to EBITDA Ratio|optinose.com - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Pharmaceuticals, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PROC|Enterprise Value to EBITDA Ratio PTPI (Petros)|Enterprise Value to Operating Income Before Depreciation Ratio QLI|EV/EBITDA Multiple SLRN (Acelyrin, Inc.)|TFFP: Enterprise Value to Operating Income Before Depreciation
